JCS Medical, Change of Major Shareholder
JCS Medical announced on the 10th that its largest shareholder is scheduled to change to Syracuse Subco.
Syracuse Subco is a corporation newly established in Korea by Archimed in April, and it announced that from this day until the 22nd of next month, it will conduct a tender offer to purchase 55,724,838 common shares of JCS Medical at 13,000 KRW per share. This corresponds to 72.0% of the total potential issued shares of JCS Medical.
The total amount is approximately 724.4 billion KRW, and NH Investment & Securities is the lead manager for the tender offer.
Hot Picks Today
KOSPI Struggles to Break 7,000 Points as Over 100 Trillion Won in Individual Investor Supply Overhang Looms
- "Even Xiaomi Isn't Immune: Soaring Memory Prices Trigger 200,000 Won Spike in Smartphone Costs"
- Packed Crowds with “It’s So Cheap!”... Japan Travel by UK Millennials & Gen Z Surges 25% in a Year
- Taiwanese Man Threw 100 Cockroaches in Restaurant... Was It Due to Service Complaints?
- "Too Tired of Seongsu and Euljiro"... Where Are Young Adults in Their 20s and 30s Going on the Hunt for Hotspots These Days?
Archimed is a France-based private equity fund management company established in 2014, primarily investing in the healthcare sector including bio-pharmaceuticals, medical technology, and in vitro diagnostics.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
